Trial Profile
A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2023
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Fludarabine (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Lenalidomide
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 26 Apr 2023 Status changed from active, no longer recruiting to completed.
- 05 Jun 2020 Status changed from completed to active, no longer recruiting.
- 26 Oct 2017 Status changed from active, no longer recruiting to completed.